{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-288305","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.699098+00:00","generated_at":"2026-06-21T16:05:46.884338+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OmniAb expects $25M milestone payment from Janssen after first US commercial sale of TECVAYLI","bullets":["Janssen notified OmniAb that first US commercial sale of TECVAYLI (teclistamab) occurred, triggering $25M milestone.","OmniAb expects to receive the $25M payment and recognize $25M milestone revenue in Q4 2022.","Milestone arises from licensing agreement between OmniAb and an affiliate of Janssen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-288305","json":"https://secwatch.observer/filing/0001193125-22-288305.json","markdown":"https://secwatch.observer/filing/0001193125-22-288305.md","text":"https://secwatch.observer/filing/0001193125-22-288305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000119312522288305/0001193125-22-288305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000119312522288305/d390698d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:05:46.884338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}